Reading RCKT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RCKT free→Reading RCKT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RCKT free→QuarterlyIQ Insights · RCKT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Completion of Acquisition or Disposition of Assets. On June 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) completed the previously disclosed sale (the “Asset Sale”) of its Rare Pediatric Disease Priority Review Voucher (“PRV”) to a large pharmaceutical company. The PRV was originally issued in connection with the FDA’s approval of the Company’s biologics license application for KRESLADI™ (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy indicated f…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.